Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

被引：0
|
作者：
Almeida, Antonio [1 ]
Santini, Valeria [2 ]
Croepper, Stefanie [3 ]
Jonasova, Anna [4 ]
Vey, Norbert [5 ]
Giagounidis, Aristoteles [3 ]
Hellstrom-Lindberg, Eva [6 ]
Mufti, Ghulam J. [7 ]
Sanz, Guillermo [8 ]
Skikne, Barry [9 ]
Hoenekopp, Albert [10 ]
Seguy, Francis [10 ]
Zhong, Jianhua [9 ]
Fenaux, Pierre [11 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal
[2] Univ Florence, AOU Careggi, Florence, Italy
[3] Marien Hosp, Dusseldorf, Germany
[4] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic
[5] Ctr Reg Lutte Canc, Inst Paoli Calmettes, Marseille, France
[6] Karolinska Univ Hosp, Stockholm, Sweden
[7] Kings Coll Hosp London, London, England
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Celgene Corp, Summit, NJ USA
[10] Celgene Int, Boudry, Switzerland
[11] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2880.2880
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
    Rufer, Axel
    Angermann, Hubert
    Benz, Rudolf
    Bonadies, Nicolas
    Calderoni, Antonello
    Cantoni, Nathan
    Efthymiou, Anna
    Escher, Robert
    Favre, Genevieve
    Friess, Dorothea
    Gschwend, Andreas
    Himmelmann, Andreas
    Holbro, Andreas
    Keller, Peter
    Kouroupi, Eirini
    Lehmann, Thomas
    Pedarnig, Nikolaus
    Rigamonti, Veronique
    Samii, Kaveh
    Schmidt, Adrian
    Schafer, Hans-Peter
    Sperb, Roland
    Stussi, Georg
    Winkler, Annette
    Zenhausern, Reinhard
    Goede, Jeroen S.
    HEMASPHERE, 2022, 6 (07):
  • [32] Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Zhong, Jianhua
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    Hoenekopp, Albert
    MacBeth, Kyle J.
    BLOOD, 2016, 128 (22)
  • [33] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
    Scharenberg, C.
    Karimi, M.
    Jansson, M.
    Walldin, G.
    Woll, P.
    Jacobsen, S. E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
  • [34] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    M A Sekeres
    A S Swern
    P Fenaux
    P L Greenberg
    G F Sanz
    J M Bennett
    F Dreyfus
    A F List
    J S Li
    M M Sugrue
    Blood Cancer Journal, 2014, 4 : e242 - e242
  • [35] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    Sekeres, M. A.
    Swern, A. S.
    Fenaux, P.
    Greenberg, P. L.
    Sanz, G. F.
    Bennett, J. M.
    Dreyfus, F.
    List, A. F.
    Li, J. S.
    Sugrue, M. M.
    BLOOD CANCER JOURNAL, 2014, 4 : e242 - e242
  • [36] Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study
    Diez-Campelo, Maria
    Yucel, Aylin
    Goyal, Ravi K.
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Jimenez, Maria
    Sluga-O'Callaghan, Martina
    Miteva, Dimana
    Xiao, Hong
    Germing, Ulrich
    BLOOD, 2022, 140 : 13308 - 13309
  • [37] Prediction of Response to Treatment with Lenalidomide in Patients with Non-Del 5q Myelodysplastic Syndrome by Gene Expression Profiling Remains Difficult.
    Hofmann, Wolf-Karsten
    Nolte, Florian
    Benlasfer, Ouidad
    Thiel, Eckhard
    Ehninger, Gerhard
    Platzbecker, Uwe
    BLOOD, 2009, 114 (22) : 1088 - 1088
  • [38] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    LEUKEMIA RESEARCH, 2017, 55 : S14 - S14
  • [39] Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
    Garcia-Manero, Guillermo
    Almeida, Antonio
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart L.
    Ozawa, Keiya
    Weaver, Jerry
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 213 - +
  • [40] A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS
    Shammo, Jamile M.
    Christopherson, Kent W., II
    Karmali, Reem
    Larson, Melissa L.
    Balla, Michelle
    Venugopal, Parameswaran
    BLOOD, 2013, 122 (21)
12345